Chronic I1-imidazoline agonism: Sympathetic mechanisms in hypertension

Hypertension

Volumn 35, Issue 6, 2000, Pages 1264-1269

  Greenwood, John P ^a   Scott, Eleanor M ^a   Stoker, John B ^a   Mary, David A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive agents; Blood pressure; Hypertension, essential; Moxonidine; Sympathetic nervous system

Indexed keywords

MOXONIDINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SYMPATHETIC TONE;

EID: 0034048025     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.6.1264     Document Type: Article

References (30)

1. Folkow B. Physiological aspect of primary hypertension. Physiol Rev. 1982;62:347-504.
2. Mark AL. Regulation of sympathetic nerve activity in mild human hypertension. J Hypertens. 1990;8(suppl 7):S67-S75.
3. Julius S, Nesbitt S. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens. 1996;9:113s-120s.
4. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86-99.
5. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13:870-877.
6. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
7. Prichard BN, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens. 1997;15(suppl 1):S47-S55.
8. 1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J Hypertens 1997; 15:117-125.
9. 2-adrenoceptor agonists in anaesthetized cats. Br J Pharmacol. 1989;98:1157-1164.
10. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994;24(suppl 1):S1-S8.
11. 1-imidazoline receptor agonist. J Cardiovasc Pharmacol. 1996;27(suppl 3):S26-S37.
12. Kirch W, Hutt H-J, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol. 1990;30:1088-1095.
13. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther. 1991;5:967-972.
14. 1-Imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension. 1998;32:1022-1027.
15. Greenwood JP, Stoker JB, Mary DASG. Quantitative assessment of single unit peripheral sympathetic discharge in human hypertensive disease. Circulation. 1999;100:1305-1310.
16. Macefield VG, Wallin BG. Firing properties of single vasoconstrictor neurones in human subjects with high levels of muscle sympathetic activity. J Physiol (Lond.). 1999;516:293-301.
17. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
18. Vallbo AB, Hagbarth K-E, Torebjork HE, Wallin BG. Somatosensory, proprioceptive and sympathetic activity in human peripheral nerves. Physiol Rev. 1979;59:919-957.
19. Sundlöf G, Wallin BG. The variability of muscle nerve sympathetic activity in resting recumbent man. J Physiol (Lond). 1977;272:383-397.
20. Eckberg DL, Sleight P. Human Baroreflexes in Health and Disease. Oxford, UK: Clarendon Press; 1992:61-77. Monographs of the Physiological Society; No. 43.
21. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects Circulation 1994;89:2634-2640.
22. Schachter M, Luszick J, Jager B, Verboom C, Sohlke E. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf. 1998;19:191-203.
23. Ollivier JP, Christen MO. I1-Imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol. 1994;24(suppl 1):S39-S48.
24. Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol. 1987;27:46-51.
25. Planitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol. 1986;29:645-650.
26. Lotti G, Gianrossi R. Moxonidine vs. captopril in minor to intermediate hypertension: double-blind study of effectiveness and tolerance. Fortschr Med. 1993;111:429-432.
27. Kuppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15:93-97.
28. Fauvel JP, Najem R, Maakel N, Pozet N, Laville M. Effects of moxonidine on stress-induced peak blood pressure and renal function: a randomized, double-blind, placebo-controlled crossover study. J Cardiovasc Pharmacol. 1998;32:495-499.
29. Karft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol. 1994;24(suppl 1):S29-S33.
30. Prichard BN, Owens CW, Graham BR. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J Hum Hypertens. 1997;11(suppl 1):S29-S45.